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Point: Minimally invasive bipolar radiofrequency ablation of lone
atrial fibrillation: Early multicenter results
Erik Beyer, MD,a Richard Lee, MD,b and Buu-Khanh Lam, MDc
Objective: The treatment of lone atrial fibrillation can be a minimally invasive procedure using bipolar radiofre-
quency ablation technologies. Our objectives were to report on the safety and early efficacy of this novel thera-
peutic modality.
Methods: At 3 North American institutions between February 2005 and August 2007, 100 patients underwent
minimally invasive bilateral pulmonary vein isolation, autonomic denervation, and left atrial appendage resec-
tion. The mean age was 65  11 years, and 70% were male. The median duration of atrial fibrillation was 5.0
years; atrial fibrillation was paroxysmal in 39 patients (39%), persistent in 29 patients (29%), and permanent
in 32 patients (32%). Indications for surgery included failure of medical therapy or percutaneous ablation and
severe symptoms. Mean follow-up was 13.6  8.2 months.
Results: The mean operative time was 253  65 minutes, and the median hospital length of stay was 5 days.
There were no intraoperative conversions and no mortality to report. Postoperative complications included pace-
maker requirement in 5 patients (5%), phrenic nerve palsy in 3 patients (3%), hemothorax in 3 patients (3%),
transient ischemic attack in 1 patient (1%), and pulmonary embolism in 1 patient (1%). At follow-up, 87%
of patients were in normal sinus rhythm (paroxysmal 93%, persistent 96%, permanent 71%; P< .05); antiar-
rhythmic therapy was discontinued in 62% of patients, and anticoagulation therapy was discontinued in 65%
of patients.
Conclusion:Minimally invasive bipolar radiofrequency ablation of lone atrial fibrillation is a safe and efficacious
therapeutic option in selected patients. Further development is needed to reduce the rate of complications. Long-
term prospective results are required to further validate this modality as a therapeutic option to treat lone atrial
fibrillation.
POINT/COUNTERPOINTAs many as 6 million Americans already have atrial fibrilla-
tion (AF).1 By 2020, AF could affect as many as 9 million
people in the United States alone. Despite advances in med-
ical therapy, medications have only been effective in restor-
ing sinus rhythm (SR) in approximately one half of all the
patients with AF.2,3 This lack of successful SR restoration
has limited the advantage of rhythm control in several large
studies.2,4 However, AF remains a major cause of stroke and
an independent risk factor for mortality.2,5,6 There is specu-
lation that improved success in SR restoration may offer
measurable survival advantages to the population with AF.2
Maze surgery was established as a curative procedure for
patients with AF more than 2 decades ago and has been sug-
gested to reduce stroke in patients with AF.7,8 Although
more intensive monitoring suggests that results may be
slightly less curative than historical reports state,9 the results
From the Scott andWhite Clinic,a Temple, Texas; Northwestern University,b Chicago,
Illinois; and University of Ottawa Heart Institute,c Ottawa, Canada.
Presented at the 88th Annual Meeting of the American Association for Thoracic Sur-
gery, May 11–14, 2008, San Diego, California.
Received for publication May 7, 2008; revisions received Oct 5, 2008; accepted for
publication Nov 17, 2008.
Address for reprints: Buu-Khanh Lam, MD, Division of Cardiac Surgery, University
of Ottawa Heart Institute, 40 Ruskin St, H3404, Ontario, Canada, K1Y 4W7
(E-mail: bklam@ottawaheart.ca).
J Thorac Cardiovasc Surg 2009;137:521-6
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2008.11.031The Journal of Thoracic andof the complete Maze procedure are clearly more successful
than catheter-based interventions.10 Unfortunately, the
Maze procedure has not been embraced as a stand-alone
procedure, with only 600 cases performed for lone AF in
the Society of Thoracic Surgeons database in 2006.11
New technologies have allowed the creation of transmural
lesions on a beating heart through alternative, less-invasive
incisions. Although many of these have demonstrated early
success,12,13 the results are often not as good in larger se-
ries.14 One of these new technologies has been the applica-
tion of bipolar radiofrequency ablation to create pulmonary
vein isolation via a bilateral thoracotomy approach.15,16
However, the series are generally small and limited to a sin-
gle institution.
The objective of this study was to examine the results of
this approach in a multi-institutional setting. In addition to
the pulmonary vein isolation, autonomic ganglionic plexi
(AGP) stimulation and ablation and left atrial (LA) append-
age ligation and resection were performed at all institutions.
PATIENTS AND METHODS
Patient Population
At 3 North American institutions between February 2005 and August
2007, 100 patients underwent thoracoscopic-assisted bilateral pulmonary
vein isolation, autonomic denervation, and LA appendage resection via
bilateral mini-thoracotomies. Main indications for surgery were failure of
medical therapy or percutaneous ablation and severe symptoms. TheCardiovascular Surgery c Volume 137, Number 3 521
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AF ¼ atrial fibrillation
AGP ¼ autonomic ganglionic plexi
LA ¼ left atrial
NSR ¼ normal sinus rhythm
SR ¼ sinus rhythm
mean age was 65  11 years. Baseline patient characteristics are described
in Table 1.
Mild aortic valvular disease was present in 17 patients (17%), whereas
mild to moderate mitral valve insufficiency was present in 58 patients
(58%) with no significant differences associated with the type of AF
(P ¼ .53). The presence of mild coronary artery disease was noted on pre-
operative angiogram in 23 patients (23%), with no significant difference
observed (P ¼ .30).
All patients with AF who were referred for minimally invasive bipolar
radiofrequency ablation had previously failed medical therapy or catheter
ablation. Some referred patients were not considered suitable candidates
if they had previous thoracic surgery leading to severe adhesions, had an en-
larged left atrium (>6.0 cm), had evidence of thrombus in the left atrium,
were not able to tolerate single lung ventilation, or were considered too
high risk because of age or comorbidities.
Definitions of Atrial Fibrillation Type
Paroxysmal AF was defined in this study as AF less than 7 days in du-
ration and self-terminated. Persistent AF was defined as AF greater than 7
days in duration or terminated by direct-current cardioversion or pharma-
cologically within 7 days. Permanent AF (recently changed to long-stand-
ing persistent) was defined as continuous AF lasting more than 1 year in
duration.
Surgical Technique
General endotracheal anesthesia is delivered via a double-lumen endo-
tracheal tube. A central line is placed, and a transesophageal echocardio-
gram is performed to determine the presence or absence of clot in the LA
appendage. If thrombus is identified, the procedure is aborted.
A video-assisted bilateral mini-thoracotomy technique is used to electri-
cally isolate the pulmonary veins. The patient is positioned in the left lateral
decubitus position, and a small incision is made at the intersection of the an-
terior axillary line and the line at the level of the xyphoid process. A 5-mm
trochar is inserted, and a 30-degree degree angled 5-mm videoscope is di-
rected through this port. An incision is made at the midaxillary line over
the fourth intercostal space, and the intercostal muscle and the pleura are di-
vided. A soft tissue retractor (CardioVations, Edwards Lifesciences Corp,
Irvine, Calif) is placed.
The pericardium is divided anterior to the phrenic nerve from the supe-
rior vena cava to the inferior vena cava. Retraction sutures are placed on the
inferior cut edge of the pericardium and brought out through separate small
stab incisions on the lateral chest wall. The oblique and transverse sinuses
are entered using blunt dissection, and an articulating lighted tip dissector
(Navigator, Medtronic Inc, Minneapolis, Minn) is placed through a separate
port. The dissector is introduced through the oblique sinus and directed pos-
terior to the right pulmonary veins. The tip of the dissector is then guided
between the right superior pulmonary vein and the right main pulmonary ar-
tery. A Silastic guide is then attached to the tip of the dissector via a guide
wire and brought back through the dissector port.
Saline-irrigated and nonirrigated bipolar radiofrequency clamps (BP2 or
Gemini, Medtronic Inc; Atricure Inc, Cincinnati, OH) are applied to the pul-
monary veins to achieve transmural lesions. The generator used to deliver
the radiofrequency energy has a digital graph that displays conductance522 The Journal of Thoracic and Cardiovascular Suof the tissue between the clamp. Once the tissue becomes electrically inert,
according to the predefined limits, a visual and audible signal is produced, as
well as to ensure electrical isolation of the pulmonary veins by both sensing
and pacing technology.
With the pulmonary veins anatomically isolated, a pacing/sensing and
ablation pen/probe (MAPS pen, Medtronic Inc or Atricure Bipolar Pen, At-
ricure Inc) is used to identify AGP and ablate them. The pen/probe is placed
in pacing mode, and high-frequency pacing (800–1000 bpm) is applied to
the fat pad overlying the right atrium and along Waterston’s groove. Atrio-
ventricular nodal slowing, as defined by a greater than 50% increase in the
R-to-R interval, is marked as a site of autonomic ganglion clusters. These
sites (Figure 1) are then ablated with the bipolar radiofrequency pen/probe.
The pen/probe is also used to document preablation electrical conductiv-
ity across the pulmonary veins by both pacing and sensing the superior and
inferior pulmonary veins. Once the baseline electrical activity is recorded,
the bipolar radiofrequency clamp is positioned around the pulmonary veins.
The Silastic guide directs the lower jaw of the clamp posterior to the right
pulmonary veins. Once the jaws of the clamp are correctly positioned
around the antrum of the pulmonary veins and onto the left atrium, bipolar
energy is delivered to the tissue. We routinely performed 3 ablations for
each lesion. After the ablation, the pulmonary veins are again tested for elec-
trical activity; the pen/probe is used to sense and pace across the pulmonary
veins. The inability to pace across the pulmonary veins (exit block) and the
absence of atrial electrical activity on the pulmonary veins during sensing
(entrance block) determine whether the PV ablation line is complete, and
therefore whether further ablations are necessary. The latter was necessary
in less than 10% of patients. The evaluation of entrance block is especially
important in the setting of patients with permanent AF in whom cardiover-
sion may not always be successful intraoperatively. The clamp is removed,
and a 24F Blake drain is placed. The port sites are closed once the right lung
is reinflated.
The patient is repositioned into the right lateral decubitus position, and
the procedure is reproduced on the left side. Instead of the fourth interspace
for the working port, the third interspace is entered. The pericardium is di-
vided posterior to the phrenic nerve from the pulmonary artery superiorly to
the inferior pulmonary veins. The ligament of Marshall is divided, and test-
ing for autonomic ganglion occurs along the Marshall tract. Entrance and
exit block testing are performed once ablation is complete.
The LA appendage is excised using a 60-mm endoGIA stapler (Auto
suture, United States Surgical Corporation, Norwalk, Conn). The stapler
is inserted through the same port as the bipolar clamp. If at the end of the
procedure the patient is in AF or atrial flutter, synchronized direct-current
cardioversion is performed.
Follow up
The mean follow-up was 13.6 8.2 months and 100% complete; all pa-
tients had at least a 24-hour Holter monitor after a blanking period of 3
months and then on a recommended yearly basis. Procedural success was
defined as the absence of AF or atrial flutter on follow-up electrocardio-
grams and Holter monitor recordings after the blanking period. Informed
consent for continuous follow-up monitoring had been given a priori by
the patients as part of a standardized protocol for this minimally invasive ab-
lative therapy. All protocols were reviewed and approved by the institu-
tional health research ethics board.
Statistical Analysis
Baseline patient characteristics were compared between patients’ groups
via chi-square test and Fisher’s exact test when frequency was less than 5.
Continuous variables were assessed using the Student t test when normally
distributed and the Wilcoxon rank-sum test when data were skewed. One-
way analysis of variance tests, with Bonferroni’s t test for the means, were
performed on continuous variables that were dependent on a classification.
The Kaplan–Meier method was used to assess time-related outcome
(recurrence of AF). Predictors of recurrence of AF were identified usingrgery c March 2009
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Characteristic All N ¼ 100 (%) Paroxysmal N ¼ 39 (%) Persistent N ¼ 29 (%) Permanent N ¼ 32 (%) P
Male 70 (70) 25 (64) 22 (76) 23 (72) .56
Age (y, mean  SD) 65  11 65  11 66  11 64  11 .85
Weight (kg) 94  18 94  18 92  15 97  21 .48
AF duration (mo) 59  46 59  46 110  106 83  43 .03
Previous DCC (no./pt) 2.4  2.1 2.1  1.1 2.5  2.3 2.7  2.5 .43
NYHA class I-II 21 (21) 2 (2) 7 (7) 12 (12) .02
Hypertension 65 (65) 29 (74) 15 (52) 21 (66) .15
Hypercholesterolemia 25 (25) 7 (18) 7 (24) 11 (34) .28
Diabetes 11 (11) 6 (15) 2 (7) 3 (9) .51
Smoking 50 (50) 13 (33) 14 (48) 23 (72) .005
COPD 5 (5) 4 (10) 1 (4) 0 .13
TIA 4 (4) 2 (5) 1 (4) 1 (3) .89
CVA 9 (9) 1 (3) 3 (10) 5 (16) .15
Family history of CAD 52 (52) 15 (39) 13 (45) 24 (75) .006
Amiodarone 22 (22) 9 (23) 7 (24) 6 (19) .86
Sotalol 8 (8) 5 (13) 2 (7) 1 (3) .31
Flecainamide 15 (15) 6 (15) 7 (24) 2 (6) .15
Beta-blockers 58 (58) 23 (59) 17 (59) 18 (56) .97
Caþþ channel blockers 22 (22) 8 (21) 5 (17) 9 (28) .57
Digoxin 21 (21) 6 (15) 5 (17) 10 (31) .22
Coumadin 78 (78) 29 (74) 20 (69) 29 (91) .09
Aspirin 19 (19) 6 (15) 10 (34) 3 (9) .03
Echocardiography
LA dimension (cm) 4.3  0.6 4.1  0.5 4.2  0.5 4.6  0.6 .0003
EF (%) 55  8.5 57  6 56  11 52  8 .04
PAP (mm Hg) 31  2.9 31  1.0 31  1.5 32  4.9 .98
AF,Atrial fibrillation;DCC, direct-current cardioversion;NYHA,NewYork Heart Association;COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack; CVA,
cerebrovascular accident; CAD, coronary artery disease; Caþþ, calcium; LA, left atrium; EF, ejection fraction; PAP, pulmonary artery pressure; SD, standard deviation.logistic regression and semiparametric multivariable Cox proportional haz-
ard modeling; variables screening ensured that an adequate (n¼ 10) number
of events was associated with a potential risk factor, and that the scales of
ordinal and continuous variables were calibrated with respect to outcome.
Variable selection proceeded in a forward stepwise manner with a liberal en-
try criterion of P less than .15 and a stay criterion of P less than .1. All anal-
yses were performed using the SAS statistical software (SAS v9.1; SAS,
Cary, NC).
RESULTS
Preoperative and Operative Characteristics
Table 1 shows the preoperative characteristics of patients
undergoing the minimally invasive ablation; of note is the
significantly longer duration of AF in patients with AF qual-
ified as persistent or permanent (P ¼ .03). These latter pa-
tients were also found to experience more dyspnea (P ¼
.02), have a greater proportion of smokers (P ¼ .005), and
have more significant LA enlargement (P ¼ .0003).
The mean operative time was 253  65 minutes. Intrao-
perative direct-current cardioversion was performed at the
conclusion of the surgical procedure in 14 patients (36%)
with paroxysmal AF, 12 patients (41%) with persistent
AF, and 21 patients (66%) with permanent AF (P ¼ .03).
The number of patients leaving the operating room in normal
sinus rhythm (NSR) was as follows: 37 (95%) with parox-The Journal of Thoracic andysmal AF, 25 (86%) with persistent AF, and 24 (75%)
with permanent AF (P ¼ .05).
Outcomes
In this series of patients, no intraoperative conversions to
sternotomy or standard thoracotomy were required. There
was no 30-day in-hospital mortality. The rate of postopera-
tive procedure-related complications was 14% and included
the need for permanent pacemaker in 5 patients (5%), post-
operative hemothorax managed conservatively in 3 patients
(3%), and phrenic nerve injury in 3 patients (3%). Pulmo-
nary embolus occurred in 1 patient (1%) and transient is-
chemic attack occurred in 1 patient (1%) on postoperative
day 2.
The mean hospital length of stay was 6.5  3.9 days
(range 2–35, median 5 days). At the time of discharge, 67 pa-
tients (67%) were in NSR, 27 patients (27%) were in AF, 1
patient (1%) was in atrial flutter, and 5 patients (5%) were in
NSR via a permanent pacemaker; there was no difference
observed in discharge rhythm between patients with parox-
ysmal, persistent, or permanent AF (P ¼ .26). Medications
at the time of discharge included amiodarone in 52 patients
(52%), sotalol in 11 patients (11%), flecainamide in 19 pa-
tients (19%), beta-blockers in 50 patients (50%), calciumCardiovascular Surgery c Volume 137, Number 3 523
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(14%), and warfarin in 86 patients (86%).
At the time of follow-up, the proportion of patients in
NSRwas 87% overall. NSRwas restored in 93% of patients
with paroxysmal AF, 96% of patients with persistent AF,
and 71% of patients with permanent AF (P¼ .03) (Figure 2).
Subjective reports of improvement in symptoms were
observed in 87% of patients with paroxysmal AF, 100%
of patients with persistent AF, and 72% of patients with
permanent AF (P ¼ .007). Antiarrhythmic drugs and warfa-
rin use were discontinued in 63% and 64% of patients, re-
spectively, with no significant difference among AF type
(P ¼ .27).
FIGURE 1. A, Right-sided AGP targeted for high-frequency stimulation
and ablation. B, Left-sided AGP targeted for high-frequency stimulation
and ablation.524 The Journal of Thoracic and Cardiovascular SuTable 2 lists predictors of recurrence of AF with the stron-
gest factor observed being the presence of permanent AF
(hazard ratio 9.3; confidence interval, 2.2–38.5). The dura-
tion of AF was not found to be a significant predictor of re-
currence of AF. There was a weak relationship observed
between the presence of active autonomic ganglia on the
left side superior pulmonary vein/ligament of Marshall areas
and the recurrence of AF (hazard ratio 3.7; confidence inter-
val, 1.1–13.2). By logistic regression, permanent AF, older
age, and presence of AF at the time of discharge from the op-
erating room were all strongly associated with recurrence of
AF. There was no difference noted in the technology (irri-
gated vs nonirrigated) to create the pulmonary vein lesions
(P ¼ .9). LA size was not found to be a predictor of failure
to restore NSR.
DISCUSSION
During the last 20 years, surgeons and electrophysiolo-
gists have been making progress toward finding a cure for
AF that offers patients an acceptable risk/benefit profile.
The full cut-and-sew Maze procedure has delivered excel-
lent results but has not been widely accepted as a stand-alone
therapy.17 Catheter-based techniques do offer a fast recovery
when successful, but they have had modest success in restor-
ing SR and still have measurable risk.10 Minimally invasive
surgical techniques represent a compromise between these 2
approaches. Previous reports with alternate approaches have
not delivered sustainable success.14 We believe that this ap-
proach offers satisfactory outcomes and brings us one step
closer to therapy that offers our patients and referring col-
leagues an acceptable risk/benefit ratio.
The use of a bilateral thoracotomy approach for AF has
been described for more than a decade.18 The reliability
of bipolar radiofrequency ablation as an alternative to
FIGURE 2. Freedom from AF in patients with paroxysmal, persistent, and
permanent AF. AF, Atrial fibrillation.rgery c March 2009
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geries in patients undergoing cardiac surgery.19 However,
its success after use on a beating heart with only the creation
of pulmonary vein islands has been limited to single-institu-
tion case series. This multi-institutional report represents the
largest experience to date and offers results from 3 surgeons.
Our early results suggest that the procedure is safe, with
a complication rate lower than those reported with the classic
Maze procedure.20 In addition, in early follow-up, the proce-
dure appears effective, particularly for paroxysmal and per-
sistent AF. The majority of patients are removed from
medication and anticoagulation, and are symptomatically
improved.
The complication rate and recovery time were still higher
than we would hope for and do not represent a benign pro-
cedure. We believe that the benefit outweighs the risk and
offers an improvement over the traditional Maze approach,
but more data are needed before making this claim. We
hope that with more experience, the complication rate will
decrease and the advance of new technology will make
this even less morbid.
We understand that the AGP play an integral role in the
induction and maintenance of AF.21 We also understand
that their destruction may only be a temporary phenome-
non,22 and thus may not lead to long-term success. The
role of this portion of the therapy needs to be more com-
pletely understood in this and all other approaches to AF
that rely on the destruction of atrial tissue.
We know that the atrial appendage plays a role in stroke in
patients with AF.23 We think that its ligation will offer
a stroke benefit and may be a major benefit of the Maze pro-
cedure. However, the amount of investigation in this area
makes any thoughts on this issue premature. More investiga-
tion, including randomized studies that answer this question,
are needed.
In this report, the mean LA dimension was close to normal
and relatively homogenous; therefore, no correlation could
be established between LA dimension and recurrence of
AF. This may have been one of the main contributors to
our encouraging early results. We do note, however, that pa-
tients with permanent AF have significantly larger LA di-
mensions than their paroxysmal and persistent counterparts.
TABLE 2. Predictors of recurrence of atrial fibrillation
Factor Coefficient ± SD P
Proportional hazard Hazard ratio (CL)
Permanent AF 2.2  0.72 .002 9.3 (2.2–38.5)
AG_L1 1.3  0.66 .05 3.7 (1.1–13.2)
Logistic regression Odds ratio (CL)
Permanent AF 3.8  1.4 .007 45.5 (2.8–75.1)
Older age 0.08  0.04 .05 1.1 (1.05–1.8)
Postoperative AF 2.7  1.1 .01 14.7 (1.9–60.5)
AF, Atrial fibrillation; AG_L1, autonomic ganglion location 1; SD, standard deviation;
CL, confidence limit.The Journal of Thoracic andLimitations
This is a multi-institution, nonrandomized, observational
clinical study in which group differences and known con-
founders were controlled for in the multivariable analysis.
Despite the adequate sample size and statistical adjustments
applied, unmeasured and unknown confounders may have
influenced the results. As those of other observational co-
horts, the results of these analyses may not be generalizable
to all patients who have undergone this procedure at other
centers.
The follow-up, although complete, remains short. The
long-term efficacy can only be known with additional fol-
low-up. Furthermore, the use of at least a 24-hour Holter
may be insufficient in the detection of recurrent tachyarrhyth-
mias; perhaps the future availability of permanent loop re-
corders in this setting will allow to us to better ascertain the
procedure’s long-term success. Until this latter becomes
standard of care, we are confident that our follow-up proto-
cols remain superior to the phone call follow-up methodol-
ogy of the initial experience with the Maze procedure.20
The bar must be raised if we are to continue to offer patients
any intervention for AF, including medical therapy.
Conclusions
We believe that this approach to AF brings us closer to
a procedure that is efficacious and offers a risk/benefit profile
that will allow a benefit to patients with AF. If the results
from this study are sustained, this approach is already a via-
ble therapeutic option for appropriate patients.
References
1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fi-
brillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the
projections for future prevalence. Circulation. 2006;114:119-25.
2. Roy H, Talajic M, Dorian P, et al. Canadian Trial of Atrial Fibrillation: amiodar-
one v. propafenone or sotalol for maintenance of sinus rhythm. N Engl J Med.
2000;342:913.
3. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm,
treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of
Rhythm Management (AFFIRM) Study. Circulation. 2002;109:1509-13.
4. Roy D, Talajic M, Nattel S, et al. Late-breaking clinical trial abstracts from the
American Heart Association’s Scientific Sessions 2007. Circulation. 2007;116:
2627-33.
5. Kannel WB, Abbott RD, Savage DD, et al. Epidemiology features of chronic
atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-22.
6. Hylek EM, D’Antonio J, Evans-Molina C, et al. Translating the results of random-
ized trials into clinical practice. Stroke. 2006;37:1075-80.
7. Cox JL, Schuessler, D’Agostino HJ Jr, et al. The surgical treatment of atrial fibril-
lation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc
Surg. 1991;101:569-83.
8. Cox JL, Ad N, Palazzo T, et al. Impact of the Maze procedure on the stroke rate in
patients with atrial fibrillation. J Thorac Cardiovasc Surg. 1999;118:833-40.
9. Stulak JM, Sundt TM, Dearani JA, et al. Ten-year experience with the Cox-Maze
procedure for atrial fibrillation: how do we define success? Ann Thorac Surg.
2007;83:1319-25.
10. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, effi-
cacy, and safety of catheter ablation for human atrial fibrillation. Circulation.
2005;111:1100-5.
11. Gammie JS, Haddad M, Milford-Beland S, et al. Atrial fibrillation correction sur-
gery: lessons from the Society of Thoracic Surgeons National Cardiac Database.
Ann Thorac Surg. 2008;85:909-14.Cardiovascular Surgery c Volume 137, Number 3 525
Point/Counterpoint Beyer et al12. Pruitt JC, Lazzara RR, Dworkin G, et al. Totally endoscopic ablation of lone atrial
fibrillation: initial clinical experience. Ann Thorac Surg. 2006;81:1325-31.
13. Ninet J, Roques X, Seitelberger R, et al. Surgical ablation of atrial fibrillation with
off-pump, epicardial, high-density focused ultrasound: results of a multicenter
trial. J Thorac Cardiovasc Surg. 2005;130:803-9.
14. Pruitt JC, Lazzara RR, Ebra G, et al. Minimally invasive surgical ablation of atrial
fibrillation: the thoracoscopic box lesion approach. J Interv Card Electrophysiol.
2007;20:83-7.
15. Wolf RK, Schneeberger EW, Osterday R, et al. Video-assisted bilateral pulmo-
nary vein isolation and left atrial appendage exclusion for atrial fibrillation.
J Thorac Cardiovasc Surg. 2005;130:797-802.
16. Sagbas E, Akpinar B, Sanisoglu I, et al. Video-assisted bilateral epicardial pulmo-
nary vein isolation for the treatment of lone atrial fibrillation. Ann Thorac Surg.
2007;83:1724-30.
17. McCarthy PM, Gillinov AM, Castle L, et al. The Cox-Maze procedure: the Cleve-
land Clinic experience. Semin Thorac Cardiovasc Surg. 2000;12:25-9.526 The Journal of Thoracic and Cardiovascular Sur18. Lee R, Takaski N, Schuessler RB, et al. The closed heart MAZE: a nonbypass sur-
gical technique. Ann Thorac Surg. 1999;67:1692-702.
19. Gillinov AM, McCarthy PM, Blackstone EH, et al. Surgical ablation of atrial fi-
brillation with bipolar radiofrequency as the primary modality. J Thorac Cardio-
vasc Surg. 2005;129:1322-9.
20. Prasad SM, Maniar HS, Camillo CJ, et al. The Cox maze III procedure for atrial
fibrillation: long-term efficacy in patients undergoing lone versus concomitant
procedures. J Thorac Cardiovasc Surg. 2003;126:1822-8.
21. Lemola K, Chartier D, Yeh YH, et al. Pulmonary vein region ablation in the ex-
perimental vagal atrial fibrillation role of pulmonary veins versus autonomic gan-
glia. Circulation. 2008;117:470-7.
22. Oh S, Zhang Y, Bibevski S, et al. Vagal denervation and atrial fibrillation induc-
ibility: epicardial fat pad ablations does not have long term effects.Heart Rhythm.
2006;3:701-8.
23. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac sur-
gical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-9.gery c March 2009
